Inventor · disambiguated record
Alexandra Leida Liana Lazetic
Also filed as: LAZETIC ALEXANDRA LEIDA LIANA
10 granted patents·11 pending applications·90 citations·filing 2012–2025
89Inventor score
Top patents by PatentIndex Score
21 records- 0194US11253547B2CD19-directed chimeric antigen receptors and uses thereof in immunotherapyNKARTA INC·Filed 2020·Granted Feb 22, 2022·11 cites·19 claims
- 0294US11154575B2Cancer immunotherapy using CD19-directed chimeric antigen receptorsNKARTA INC·Filed 2020·Granted Oct 26, 2021·10 cites·25 claims
- 0394US11141436B2Immune cells engineered to express CD19-directed chimeric antigen receptors and uses thereof in immunotherapyNKARTA INC·Filed 2020·Granted Oct 12, 2021·8 cites·16 claims
- 0493US9409995B2PTK7 modulators and methods of useFOORD ORIT·Filed 2012·Granted Aug 9, 2016·39 cites·29 claims
- 0592US11365236B2Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapyNAT UNIV SINGAPORE·Filed 2018·Granted Jun 21, 2022·13 cites·6 claims
- 0689US12398187B2CD19-directed chimeric antigen receptors and uses thereof in immunotherapyNKARTA INC·Filed 2022·Granted Aug 26, 2025·1 cites·24 claims
- 0789US10836831B2Anti-PTK7 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2018·Granted Nov 17, 2020·3 cites·23 claims
- 0888US12012458B2Genetically modified natural killer cells for CD70-directed cancer immunotherapyNKARTA INC·Filed 2021·Granted Jun 18, 2024·2 cites·26 claims
- 0982US9914784B2PTK7 modulators and methods of useABBVIE STEMCENTRX LLC·Filed 2016·Granted Mar 13, 2018·3 cites·19 claims
- 1075US2025296970A1Cd19-directed chimeric antigen receptors and uses thereof in immunotherapyNKARTA INC·Filed 2025·Application pending·0 cites
- 1173US12351617B2Immune cells comprising truncated NKG2D chimeric receptorsNAT UNIV SINGAPORE·Filed 2022·Granted Jul 8, 2025·0 cites·8 claims
- 1272US2025388645A1Immune Cells Comprising Truncated NKG2D Chimeric ReceptorsNAT UNIV SINGAPORE·Filed 2025·Application pending·0 cites
- 1371US2024360234A1Genetically modified natural killer cells for cd70-directed cancer immunotherapyNKARTA INC·Filed 2024·Application pending·0 cites
- 1463US2024358758A1Methods for treatment of autoimmune diseasesNKARTA INC·Filed 2024·Application pending·0 cites
- 1561US2025339528A1Selection of optimal cell donors and methods and compositions for enhanced expansion and cytotoxicity of donor cellsNKARTA INC·Filed 2022·Application pending·0 cites
- 1659US2023390392A1Multiplex gene edited cells for cd70-directed cancer immunotherapyNKARTA INC·Filed 2023·Application pending·0 cites
- 1757US2025319185A1Bcma-directed cellular immunotherapy compositions and methodsNKARTA INC·Filed 2022·Application pending·0 cites
- 1854US2022411754A1Methods and compositions for enhanced expansion and cytotoxicity of natural killer cellsNKARTA INC·Filed 2020·Application pending·0 cites
- 1952US2024335536A1Methods of engineering immune cells for enhanced potency and persistence and uses of engineered cells in immunotherapyNKARTA INC·Filed 2021·Application pending·0 cites
- 2050US2023265390A1Enhanced expansion and cytotoxicity of engineered natural killer cells and uses thereofNKARTA INC·Filed 2021·Application pending·0 cites
- 2149US2023028399A1Bcma-directed cellular immunotherapy compositions and methodsNKARTA INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Alexandra Leida Liana Lazetic files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →